The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral Hypoglycemic Agents (OHAs) Market Research Report 2025
Synopsis
Oral hypoglycemic agents (OHAs) are a group of drugs used to help reduce the amount of sugar present in the blood. They are not insulin, but they stimulate the pancreas to produce insulin.
The global Oral Hypoglycemic Agents (OHAs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Agents (OHAs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Agents (OHAs).
Report Scope
The Oral Hypoglycemic Agents (OHAs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Hypoglycemic Agents (OHAs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Hypoglycemic Agents (OHAs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Bayer
Bristol-Myers Squibb
Novonordisk
Sanofi-Aventis
Servier
Huadong Medicine
Wanbang Biopharmaceuticals
Double-Crane Pharmaceutical
Guangzhou Pharmaceutical
Segment by Type
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Segment by Application
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Hypoglycemic Agents (OHAs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Hypoglycemic Agents (OHAs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Oral hypoglycemic agents (OHAs) are a group of drugs used to help reduce the amount of sugar present in the blood. They are not insulin, but they stimulate the pancreas to produce insulin.
The global Oral Hypoglycemic Agents (OHAs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Agents (OHAs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Agents (OHAs).
Report Scope
The Oral Hypoglycemic Agents (OHAs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Hypoglycemic Agents (OHAs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Hypoglycemic Agents (OHAs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Bayer
Bristol-Myers Squibb
Novonordisk
Sanofi-Aventis
Servier
Huadong Medicine
Wanbang Biopharmaceuticals
Double-Crane Pharmaceutical
Guangzhou Pharmaceutical
Segment by Type
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Segment by Application
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Hypoglycemic Agents (OHAs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Hypoglycemic Agents (OHAs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oral Hypoglycemic Agents (OHAs) Market Overview
1.1 Product Overview and Scope of Oral Hypoglycemic Agents (OHAs)
1.2 Oral Hypoglycemic Agents (OHAs) Segment by Type
1.2.1 Global Oral Hypoglycemic Agents (OHAs) Market Value Comparison by Type (2024-2030)
1.2.2 Sulfonylureas
1.2.3 Metformin
1.2.4 Thiazolidinediones
1.2.5 Alpha-Glucosidase Inhibitors
1.3 Oral Hypoglycemic Agents (OHAs) Segment by Application
1.3.1 Global Oral Hypoglycemic Agents (OHAs) Market Value by Application: (2024-2030)
1.3.2 Type 2 Diabetes Mellitus
1.3.3 Type 1 Diabetes Mellitus
1.4 Global Oral Hypoglycemic Agents (OHAs) Market Size Estimates and Forecasts
1.4.1 Global Oral Hypoglycemic Agents (OHAs) Revenue 2019-2030
1.4.2 Global Oral Hypoglycemic Agents (OHAs) Sales 2019-2030
1.4.3 Global Oral Hypoglycemic Agents (OHAs) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Hypoglycemic Agents (OHAs) Market Competition by Manufacturers
2.1 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral Hypoglycemic Agents (OHAs) Average Price by Manufacturers (2019-2024)
2.4 Global Oral Hypoglycemic Agents (OHAs) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Hypoglycemic Agents (OHAs), Product Type & Application
2.7 Oral Hypoglycemic Agents (OHAs) Market Competitive Situation and Trends
2.7.1 Oral Hypoglycemic Agents (OHAs) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Hypoglycemic Agents (OHAs) Players Market Share by Revenue
2.7.3 Global Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Hypoglycemic Agents (OHAs) Retrospective Market Scenario by Region
3.1 Global Oral Hypoglycemic Agents (OHAs) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Hypoglycemic Agents (OHAs) Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2019-2030
3.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2019-2024
3.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2025-2030
3.3 Global Oral Hypoglycemic Agents (OHAs) Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2019-2030
3.3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2019-2024
3.3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2025-2030
3.4 North America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
3.4.1 North America Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2019-2030)
3.4.3 North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
3.5.1 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2019-2030)
3.5.3 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Country (2019-2030)
3.6.3 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
3.7.1 Latin America Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2019-2030)
3.7.3 Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2019-2030)
4.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2019-2024)
4.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2025-2030)
4.1.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2019-2030)
4.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2019-2030)
4.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2019-2024)
4.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2025-2030)
4.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2019-2030)
4.3 Global Oral Hypoglycemic Agents (OHAs) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2019-2030)
5.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2019-2024)
5.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2025-2030)
5.1.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2019-2030)
5.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2019-2030)
5.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2019-2024)
5.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2025-2030)
5.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2019-2030)
5.3 Global Oral Hypoglycemic Agents (OHAs) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Corporation Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Novonordisk
6.5.1 Novonordisk Corporation Information
6.5.2 Novonordisk Description and Business Overview
6.5.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.5.5 Novonordisk Recent Developments/Updates
6.6 Sanofi-Aventis
6.6.1 Sanofi-Aventis Corporation Information
6.6.2 Sanofi-Aventis Description and Business Overview
6.6.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.6.5 Sanofi-Aventis Recent Developments/Updates
6.7 Servier
6.6.1 Servier Corporation Information
6.6.2 Servier Description and Business Overview
6.6.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.7.5 Servier Recent Developments/Updates
6.8 Huadong Medicine
6.8.1 Huadong Medicine Corporation Information
6.8.2 Huadong Medicine Description and Business Overview
6.8.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.8.5 Huadong Medicine Recent Developments/Updates
6.9 Wanbang Biopharmaceuticals
6.9.1 Wanbang Biopharmaceuticals Corporation Information
6.9.2 Wanbang Biopharmaceuticals Description and Business Overview
6.9.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates
6.10 Double-Crane Pharmaceutical
6.10.1 Double-Crane Pharmaceutical Corporation Information
6.10.2 Double-Crane Pharmaceutical Description and Business Overview
6.10.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.10.5 Double-Crane Pharmaceutical Recent Developments/Updates
6.11 Guangzhou Pharmaceutical
6.11.1 Guangzhou Pharmaceutical Corporation Information
6.11.2 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Description and Business Overview
6.11.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
6.11.5 Guangzhou Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Hypoglycemic Agents (OHAs) Industry Chain Analysis
7.2 Oral Hypoglycemic Agents (OHAs) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Hypoglycemic Agents (OHAs) Production Mode & Process
7.4 Oral Hypoglycemic Agents (OHAs) Sales and Marketing
7.4.1 Oral Hypoglycemic Agents (OHAs) Sales Channels
7.4.2 Oral Hypoglycemic Agents (OHAs) Distributors
7.5 Oral Hypoglycemic Agents (OHAs) Customers
8 Oral Hypoglycemic Agents (OHAs) Market Dynamics
8.1 Oral Hypoglycemic Agents (OHAs) Industry Trends
8.2 Oral Hypoglycemic Agents (OHAs) Market Drivers
8.3 Oral Hypoglycemic Agents (OHAs) Market Challenges
8.4 Oral Hypoglycemic Agents (OHAs) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
